Literature DB >> 11257187

Analysis of the molecules involved in human T-cell leukaemia virus type 1 entry by a vesicular stomatitis virus pseudotype bearing its envelope glycoproteins.

Kazu Okuma1, Yoshiharu Matsuura2, Hironobu Tatsuo1, Yoshio Inagaki3, Minoru Nakamura1, Naoki Yamamoto3, Yusuke Yanagi1.   

Abstract

Cellular entry of human T-cell leukaemia virus type 1 (HTLV-1) was studied by a quantitative assay system using vesicular stomatitis virus (VSV) pseudotypes in which a recombinant VSV (VSVDeltaG*) containing the gene for green fluorescent protein instead of the VSV G protein gene was complemented with viral envelope glycoproteins in trans. Most of the cell lines tested showed susceptibility to VSVDeltaG* complemented with either HTLV-1 envelope glycoproteins (VSVDeltaG*-Env) or VSV G protein (VSVDeltaG*-G), but not to VSVDeltaG* alone, indicating that cell-free HTLV-1 could infect many cell types from several species. High concentration pronase treatment of cells reduced their susceptibility to VSVDeltaG*-Env, while trypsin treatment, apparently, did not. Treatment of the cells with sodium periodate, heparinase, heparitinase, phospholipase A2 or phospholipase C reduced the susceptibility of cells to VSVDeltaG*-Env, but not to VSVDeltaG* complemented with measles virus (Edmonston strain) H and F proteins (VSVDeltaG*-EdHF), which was used as a control. Purified phosphatidylcholine also inhibited the infectivity of VSVDeltaG*-Env, but not VSVDeltaG*-G. These findings indicated that, in addition to cell surface proteins, glycosaminoglycans and phospholipids play an important role in the process of cell-free HTLV-1 entry.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11257187     DOI: 10.1099/0022-1317-82-4-821

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  20 in total

1.  Potential role for a carbohydrate moiety in anti-Candida activity of human oral epithelial cells.

Authors:  C Steele; J Leigh; R Swoboda; H Ozenci; P L Fidel
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

2.  Complementing defective viruses that express separate paramyxovirus glycoproteins provide a new vaccine vector approach.

Authors:  Anasuya Chattopadhyay; John K Rose
Journal:  J Virol       Date:  2010-12-22       Impact factor: 5.103

3.  Vaginal and oral epithelial cell anti-Candida activity.

Authors:  Fatema Nomanbhoy; Chad Steele; Junko Yano; Paul L Fidel
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

4.  Similar regulation of cell surface human T-cell leukemia virus type 1 (HTLV-1) surface binding proteins in cells highly and poorly transduced by HTLV-1-pseudotyped virions.

Authors:  Kathryn S Jones; Manisha Nath; Cari Petrow-Sadowski; Andrea C Baines; Megan Dambach; Ying Huang; Francis W Ruscetti
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

5.  Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines.

Authors:  Michael A Whitt
Journal:  J Virol Methods       Date:  2010-08-13       Impact factor: 2.014

6.  A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.

Authors:  Alex B Ryder; Linda Buonocore; Leatrice Vogel; Raffael Nachbagauer; Florian Krammer; John K Rose
Journal:  J Virol       Date:  2014-12-24       Impact factor: 5.103

7.  SpyAD, a moonlighting protein of group A Streptococcus contributing to bacterial division and host cell adhesion.

Authors:  Marilena Gallotta; Giovanni Gancitano; Giampiero Pietrocola; Marirosa Mora; Alfredo Pezzicoli; Giovanna Tuscano; Emiliano Chiarot; Vincenzo Nardi-Dei; Anna Rita Taddei; Simonetta Rindi; Pietro Speziale; Marco Soriani; Guido Grandi; Immaculada Margarit; Giuliano Bensi
Journal:  Infect Immun       Date:  2014-04-28       Impact factor: 3.441

8.  A chimeric vesiculo/alphavirus is an effective alphavirus vaccine.

Authors:  Anasuya Chattopadhyay; Eryu Wang; Robert Seymour; Scott C Weaver; John K Rose
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

9.  Development of a novel surrogate virus for human T-cell leukemia virus type 1: inhibition of infection by osteoprotegerin.

Authors:  Kazu Okuma; Kevin P Dalton; Linda Buonocore; Elizabeth Ramsburg; John K Rose
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

10.  Use of vesicular stomatitis virus pseudotypes bearing hantaan or seoul virus envelope proteins in a rapid and safe neutralization test.

Authors:  Michiko Ogino; Hideki Ebihara; Byoung-Hee Lee; Koichi Araki; Ake Lundkvist; Yoshihiro Kawaoka; Kumiko Yoshimatsu; Jiro Arikawa
Journal:  Clin Diagn Lab Immunol       Date:  2003-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.